File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/cen.13229
- Scopus: eid_2-s2.0-84994701998
- PMID: 27611701
- WOS: WOS:000393453400006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes
Title | Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes |
---|---|
Authors | |
Issue Date | 2017 |
Publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664 |
Citation | Clinical Endocrinology, 2017, v. 86 n. 1, p. 37-43 How to Cite? |
Abstract | OBJECTIVE: Fibroblast growth factor 21 (FGF21) improves glucose and lipid metabolism, but high circulating levels are found in type 2 diabetes, suggesting FGF21 resistance. Serum FGF21 predicts incident diabetes, but its performance compared to established and emerging predictors is not known. We aimed to study the performance of FGF21 in diabetes prediction, relative to other adipokines and established risk factors including 2-h plasma glucose (2hG) during the oral glucose tolerance test (OGTT).
DESIGN/PARTICIPANTS/MEASUREMENTS: We studied 1380 nondiabetic subjects from the Hong Kong Cardiovascular Risk Factor Prevalence Study using the second visit (2000-2004) as baseline when serum levels of FGF21 and other adipokines were measured. Glycaemic status was assessed by OGTT. Incident diabetes was defined as fasting glucose level (FG) ≥ 7 mmol/l or 2hG ≥ 11·1 mmol/l or use of antidiabetic agents, at subsequent visits.
RESULTS: A total of 123 participants developed diabetes over 9·0 years (median). On multivariable logistic regression analysis, FGF21 (P = 0·003), adipocyte fatty acid-binding protein (P = 0·003) and adiponectin (P = 0·035) were independent predictors of incident diabetes. FGF21 had the best change in log likelihood when added to a diabetes prediction model (DP) based on age, family history, smoking, hypertension, BMI, dyslipidaemia and FG. It also improved the area under ROC curve (AUROC) of diabetes prediction (DP) from 0·797 to 0·819 (P = 0·0072), rendering its performance comparable to the 'DP + 2hG' model (AUROC=0·838, P = 0·19).
CONCLUSIONS: As a biomarker for diabetes prediction, serum FGF21 appeared to be superior to other adipokines and, on its own, could be considered as an alternative to the OGTT.
© 2016 John Wiley & Sons Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/240930 |
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 0.978 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Woo, YC | - |
dc.contributor.author | Lee, CHP | - |
dc.contributor.author | Fong, HY | - |
dc.contributor.author | Xu, A | - |
dc.contributor.author | Tso, AWK | - |
dc.contributor.author | Cheung, BMY | - |
dc.contributor.author | Lam, KSL | - |
dc.date.accessioned | 2017-05-22T09:19:39Z | - |
dc.date.available | 2017-05-22T09:19:39Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Clinical Endocrinology, 2017, v. 86 n. 1, p. 37-43 | - |
dc.identifier.issn | 0300-0664 | - |
dc.identifier.uri | http://hdl.handle.net/10722/240930 | - |
dc.description.abstract | OBJECTIVE: Fibroblast growth factor 21 (FGF21) improves glucose and lipid metabolism, but high circulating levels are found in type 2 diabetes, suggesting FGF21 resistance. Serum FGF21 predicts incident diabetes, but its performance compared to established and emerging predictors is not known. We aimed to study the performance of FGF21 in diabetes prediction, relative to other adipokines and established risk factors including 2-h plasma glucose (2hG) during the oral glucose tolerance test (OGTT). DESIGN/PARTICIPANTS/MEASUREMENTS: We studied 1380 nondiabetic subjects from the Hong Kong Cardiovascular Risk Factor Prevalence Study using the second visit (2000-2004) as baseline when serum levels of FGF21 and other adipokines were measured. Glycaemic status was assessed by OGTT. Incident diabetes was defined as fasting glucose level (FG) ≥ 7 mmol/l or 2hG ≥ 11·1 mmol/l or use of antidiabetic agents, at subsequent visits. RESULTS: A total of 123 participants developed diabetes over 9·0 years (median). On multivariable logistic regression analysis, FGF21 (P = 0·003), adipocyte fatty acid-binding protein (P = 0·003) and adiponectin (P = 0·035) were independent predictors of incident diabetes. FGF21 had the best change in log likelihood when added to a diabetes prediction model (DP) based on age, family history, smoking, hypertension, BMI, dyslipidaemia and FG. It also improved the area under ROC curve (AUROC) of diabetes prediction (DP) from 0·797 to 0·819 (P = 0·0072), rendering its performance comparable to the 'DP + 2hG' model (AUROC=0·838, P = 0·19). CONCLUSIONS: As a biomarker for diabetes prediction, serum FGF21 appeared to be superior to other adipokines and, on its own, could be considered as an alternative to the OGTT. © 2016 John Wiley & Sons Ltd. | - |
dc.language | eng | - |
dc.publisher | Wiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664 | - |
dc.relation.ispartof | Clinical Endocrinology | - |
dc.rights | This is the accepted version of the following article: Clinical Endocrinology, 2017, v. 86 n. 1, p. 37-43, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1111/cen.13229/abstract | - |
dc.title | Serum fibroblast growth factor 21 is a superior biomarker to other adipokines in predicting incident diabetes | - |
dc.type | Article | - |
dc.identifier.email | Woo, YC: wooyucho@hku.hk | - |
dc.identifier.email | Lee, CHP: pchlee@hku.hk | - |
dc.identifier.email | Fong, HY: kalofong@hku.hk | - |
dc.identifier.email | Xu, A: amxu@hkucc.hku.hk | - |
dc.identifier.email | Tso, AWK: awktso@hku.hk | - |
dc.identifier.email | Cheung, BMY: mycheung@hku.hk | - |
dc.identifier.email | Lam, KSL: ksllam@hku.hk | - |
dc.identifier.authority | Lee, CHP=rp02043 | - |
dc.identifier.authority | Xu, A=rp00485 | - |
dc.identifier.authority | Tso, AWK=rp00535 | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.identifier.authority | Lam, KSL=rp00343 | - |
dc.description.nature | postprint | - |
dc.identifier.doi | 10.1111/cen.13229 | - |
dc.identifier.pmid | 27611701 | - |
dc.identifier.scopus | eid_2-s2.0-84994701998 | - |
dc.identifier.hkuros | 272172 | - |
dc.identifier.volume | 86 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 37 | - |
dc.identifier.epage | 43 | - |
dc.identifier.isi | WOS:000393453400006 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0300-0664 | - |